Withdrawal Akathisia: What It Feels Like and How Long It Lasts

Withdrawal akathisia usually lasts 1 to 4 weeks once the taper is held steady, and weeks to months after an abrupt stop. It is an intense inner restlessness, a physical compulsion to keep moving, triggered when antidepressant dose drops faster than the nervous system can adapt. Akathisia from antidepressant withdrawal is distinct from anxiety, it is documented in the clinical literature, and it responds to slowing or pausing the taper rather than pushing through.

How long does akathisia last after stopping medication?

For most people, withdrawal akathisia settles within 1 to 4 weeks after the dose is held steady. Duration tracks how steeply the dose dropped and how long the medication was taken, not willpower or psychiatric history.

Situation	Typical duration of akathisia	What usually shifts it
Mild akathisia, taper slowed or paused	1 to 4 weeks	Holding the current dose until symptoms settle
Moderate akathisia during an ongoing taper	2 to 6 weeks	Pausing, then resuming with much smaller reductions
After an abrupt stop or a very fast taper	Weeks to months	Reinstating a stabilizing dose, then re-tapering slowly
Tardive akathisia, emerging late or persisting	Months, sometimes longer	Needs a clinician; do not manage this alone

Holding the dose is the single most reliable intervention. A systematic review of post-acute withdrawal syndrome after stopping antidepressants (Hengartner and colleagues, 2025) found that a minority of people experience symptoms lasting well beyond the expected few weeks, particularly after long-term use and rapid discontinuation.

Tardive akathisia is the exception to the reassuring numbers. Tardive akathisia is restlessness that appears late, often after the medication is fully stopped, and persists rather than fading. It is less common in antidepressant withdrawal than in antipsychotic treatment, but when restlessness continues past a few months with no sign of improvement, that warrants a clinician who knows the withdrawal literature, not another dose reduction.

Bottom line: expect 1 to 4 weeks with a held dose, weeks to months after an abrupt stop, and get clinical help if akathisia persists past a few months.

What akathisia from antidepressant withdrawal actually is

Akathisia is a neurological state of inner restlessness with an urgent, hard to resist compulsion to move, usually in the legs but sometimes the whole body. The word comes from Greek meaning "not sitting." People describe crawling sensations inside the limbs and an agitation that pacing temporarily relieves but never resolves.

Akathisia was first described in the context of antipsychotic medications, which block dopamine receptors and can produce severe movement-related side effects. It is now well documented in both antidepressant use and antidepressant withdrawal. The Barnes Akathisia Rating Scale, published by Thomas Barnes in the British Journal of Psychiatry in 1989 and still the standard research instrument, separates objective akathisia (visible shifting, rocking, pacing) from subjective akathisia (the inner urge itself). Both forms appear in withdrawal.

What makes withdrawal akathisia particularly difficult is that it is often invisible to observers. Someone sitting still can be in profound inner torment. The absence of outward movement does not mean the person is comfortable, and that invisibility drives underreporting and missed diagnosis, because clinicians may not think to ask the right question.

Akathisia is not a character flaw, a relapse, or evidence that someone cannot handle stopping their medication. Akathisia is a physiological response to a neurological change, and naming it correctly is what makes it manageable.

Bottom line: akathisia is an inner movement urge with a known mechanism, not anxiety and not relapse.

How antidepressant withdrawal triggers akathisia

Most antidepressants increase serotonin availability in synapses by blocking reuptake. After prolonged use, the brain adapts by downregulating serotonin receptors and changing how those receptors respond. When the medication is reduced or stopped, serotonin availability drops sharply and the brain has to readjust.

Serotonin exerts inhibitory effects on the dopaminergic pathways involved in motor control and emotional regulation. When serotonin drops rapidly, that inhibitory brake loosens, dopaminergic activity rises in some regions, and the result can be the restless, agitated state characteristic of akathisia.

The speed of discontinuation matters more than almost anything else. Horowitz and Taylor (2019), in The Lancet Psychiatry, showed that the relationship between antidepressant dose and serotonin transporter occupancy is hyperbolic rather than linear. Cuts made at low doses have far greater neurological impact than the same milligram reduction made at a high dose. A drop from 10 mg to 5 mg of an SSRI changes receptor occupancy much more than a drop from 40 mg to 35 mg. That pharmacology explains why akathisia tends to emerge in the later stages of a taper or after an abrupt stop.

The scale of the problem is not small. Davies and Read (2019) found in a systematic review that roughly half of people who stop antidepressants experience withdrawal symptoms, and about half of those describe them as severe.

Bottom line: withdrawal akathisia is driven by how fast serotonin signalling falls, which is why the last few milligrams are the riskiest part of a taper.

Recognizing withdrawal akathisia: what it feels and looks like

The distinguishing feature of akathisia is the compelling need to move. People with akathisia feel that walking or pacing gives temporary relief from the inner restlessness, even when they know they have been walking for an hour and nothing has changed.

People in antidepressant withdrawal commonly describe restlessness deep inside the legs or throughout the body that stretching and position changes do not touch. A sense of inner vibration or buzzing. Difficulty sitting still for even a few minutes. Urges to get up and pace during conversations, meals, or at bedtime. Agitation that worsens in the evening. Emotional dysphoria, irritability, and a feeling of impending doom running alongside the physical restlessness.

That emotional component is why akathisia is associated with increased suicide risk, a link documented in early research on antipsychotic-induced akathisia and raised more recently in the antidepressant literature by groups including RxISK, which collects reports of drug-induced harm. The combination of physical torment and emotional despair is overwhelming, especially for someone who does not know these symptoms have a name and a mechanism. If akathisia is pushing you toward thoughts of self-harm, that is an emergency and needs same-day help, not a wait-and-see.

Feature	Withdrawal akathisia	Anxiety	Restless legs syndrome
Core experience	Inner urge to move, whole body	Fear, worry, racing thoughts	Creeping discomfort in the legs
Does movement help?	Yes, temporarily, and the urge returns	Not reliably	Yes, while moving
Timing	Follows a dose change within days to weeks	Any time, often situational	Evening and night, chronic
Body area	Legs, torso, arms, sometimes internal only	No specific area	Legs almost exclusively
Best for telling them apart	"Do I feel better when I pace?"	"Am I afraid of something?"	"Is it only my legs, every night?"

Bottom line: ask whether movement relieves the feeling. A yes points toward akathisia and away from ordinary anxiety.

Which antidepressants most often cause withdrawal akathisia

Risk tracks half-life, receptor binding affinity, and how abruptly the drug is stopped. Paroxetine (Paxil) has the shortest half-life of the common SSRIs and the highest binding affinity, and it is consistently associated with the fastest and most severe withdrawal, akathisia included. Venlafaxine (Effexor) carries the same profile among SNRIs.

Fluoxetine (Prozac) has an unusually long half-life and effectively tapers itself over several weeks, so withdrawal akathisia is uncommon with fluoxetine. Sertraline (Zoloft), escitalopram (Lexapro), and citalopram (Celexa) sit in between with moderate half-lives and moderate risk.

Duloxetine (Cymbalta) carries high discontinuation risk from a short half-life combined with dual serotonin and norepinephrine action. Desvenlafaxine (Pristiq) and levomilnacipran share that pattern. The FDA label for paroxetine carries explicit discontinuation warnings, and prescribing information for the short half-life agents says the same.

The NICE guideline on medicines associated with dependence or withdrawal symptoms (NG215) and the Royal College of Psychiatrists' guidance on stopping antidepressants both state that withdrawal symptoms are more severe and more common after long-term use, higher doses, and rapid reduction.

Bottom line: paroxetine, venlafaxine, and duloxetine carry the highest withdrawal akathisia risk; fluoxetine carries the lowest.

I've been tapering for months and suddenly can't sit still. What should I do?

Stop reducing. Hold the current dose and stay there until the restlessness settles, which usually takes 1 to 4 weeks. Akathisia appearing mid-taper is a signal that the pace has outrun the nervous system, and continuing to cut on schedule reliably makes it worse.

Once symptoms settle, resume with much smaller steps. Reductions of 5 to 10 percent of the current dose, made no more often than every 4 to 6 weeks, are the approach supported by the hyperbolic tapering model and by the deprescribing guidance collected at Deprescribing.org. Each reduction gets smaller in absolute terms as the dose falls, which is the point. Our taper planner will map the shape of those reductions against receptor occupancy, and the tapering plan worksheet walks through building the schedule.

If the akathisia started after a complete stop rather than mid-taper, reinstating a portion of the previous dose usually settles the symptom within days. Reinstatement works best when it happens early, within the first few weeks, and works less predictably the longer someone has been off. Reinstatement decisions belong with a prescriber, because the right reinstatement dose is often much lower than the dose someone stopped from.

Track what you are experiencing while you do this. Daily notes on severity, time of day, and how many days since the last dose change turn a vague "I feel awful" into a pattern a prescriber can act on. The symptom journal is built for that record.

Bottom line: hold the dose, wait for stabilization, then resume with reductions of 5 to 10 percent of the current dose.

What actually helps while withdrawal akathisia settles

Slowing or pausing the taper is the intervention that changes the trajectory. Everything else below manages the intensity while the nervous system catches up.

Gentle movement offers real, if temporary, relief, precisely because akathisia compels movement. Walking, swimming, and other low-intensity activity interrupt the feedback loop of inner restlessness. High-intensity exercise often worsens agitation, so the test is whether the activity feels settling or stimulating.

Some people find partial relief from magnesium, vitamin B6, or propranolol, a beta-blocker with the strongest evidence base among drug treatments for antipsychotic-induced akathisia. Propranolol has not been studied in controlled trials for withdrawal akathisia specifically. Any medication added during a taper should go through a prescriber, because adding and subtracting drugs at the same time makes it impossible to tell what is causing what.

Cold compresses, grounding techniques, and slow diaphragmatic breathing reduce the intensity of an episode without curing it. Sleep is frequently wrecked by the evening worsening pattern, and a cool room, white noise, and a consistent schedule protect whatever sleep is available during the stabilization window.

What does not help: pushing through on the original taper schedule, being told the restlessness is the original anxiety returning, or adding a second psychiatric medication to suppress a withdrawal symptom. Patient-side accounts collected by Mad in America and the withdrawal resources at Inner Compass Initiative document how often that second path lengthens the problem.

Bottom line: hold the dose, move gently, protect sleep, and do not stack a new medication on top of a withdrawal symptom.

How to explain withdrawal akathisia to a prescriber who has not seen it

Many prescribers are unfamiliar with akathisia in the context of antidepressant withdrawal, because the symptom has historically been taught in relation to antipsychotics and withdrawal is undertaught generally.

Specific language helps. Describe the inner restlessness, the urge to move, the temporary relief from pacing, and the timing relative to the dose change. Naming the Barnes Akathisia Rating Scale, NICE NG215, or the Royal College of Psychiatrists' position on stopping antidepressants moves the conversation from "you seem anxious" to a shared clinical framework.

Bring the record. A dated log of severity, time of day, and dose changes is far more persuasive than recall in a 10 minute appointment, and it lets the prescriber see the relationship between the reduction and the symptom.

If your prescriber will not engage with the possibility of withdrawal, finding one who will is a reasonable next step rather than a confrontation. Our deprescriber directory lists clinicians who work with tapering patients.

Bottom line: bring specific language, a dated symptom log, and a named guideline to the appointment.

Frequently asked questions

Does akathisia go away after stopping medication?

In most cases, yes. Akathisia that appears during a taper usually resolves within 1 to 4 weeks once the dose is held steady. Akathisia that appears after an abrupt stop takes longer, often weeks to months, and frequently settles within days if a stabilizing dose is reinstated early. A small number of people develop tardive akathisia that persists for months, and that presentation needs a clinician familiar with withdrawal rather than a faster taper.

What is withdrawal akathisia?

Withdrawal akathisia is inner restlessness with a compulsion to move, triggered by reducing or stopping a psychiatric medication rather than by taking one. It follows a dose change within days to weeks, it is relieved temporarily by pacing, and it is often accompanied by emotional dysphoria and a sense of dread. Withdrawal akathisia reflects the nervous system adjusting to a sudden drop in serotonergic signalling, not a return of the original condition.

Is akathisia the same as anxiety?

No. Anxiety is primarily cognitive and emotional, driven by stress response pathways. Akathisia is a movement-urge phenomenon rooted in disrupted dopaminergic and serotonergic signalling. The clearest separator is that movement temporarily relieves akathisia and does not reliably relieve anxiety. Both can appear together during antidepressant withdrawal, and telling them apart determines whether the answer is slowing the taper or something else.

Can all antidepressants cause akathisia during withdrawal?

Any antidepressant that meaningfully affects serotonin can produce akathisia on discontinuation, but the risk varies a lot. Short-acting drugs with high receptor binding affinity, such as paroxetine and venlafaxine, carry the highest risk. Long-acting fluoxetine carries the lowest. Vortioxetine and vilazodone have different receptor profiles and a thinner withdrawal evidence base.

What is the difference between akathisia and restless legs syndrome?

Restless legs syndrome involves an urge to move the legs specifically, worsens at night, is relieved by movement, and comes with a creeping sensation in the legs. Akathisia involves the whole body, is not limited to the legs, and carries a broader inner agitation and emotional dysphoria that restless legs syndrome does not. Restless legs syndrome is a chronic primary disorder; withdrawal akathisia is a time-limited pharmacological event tied to a dose change.

Can tapering more slowly prevent akathisia?

Slowing the taper reduces the steepness of the drop at each step and gives the brain time to adapt before the next reduction. The hyperbolic tapering research by Horowitz and Taylor (2019) supports smaller reductions, particularly at low doses where occupancy changes are proportionally largest, producing fewer and milder withdrawal symptoms. Slower tapering does not guarantee akathisia will not appear, but it substantially lowers the risk.

Moving forward

Akathisia from antidepressant withdrawal is real, recognized in the clinical literature, and in most cases time-limited. The response that works is to stop reducing, hold the dose, let the nervous system stabilize over 1 to 4 weeks, and only then decide whether the taper resumes at a much gentler pace.

taper.community is a free peer forum and resource library for people coming off psychiatric medication, organized around hyperbolic tapering and small proportional dose reductions. Members who have been through akathisia share what the weeks actually looked like in the forums.

---

Medical disclaimer: This article is for informational purposes only and does not constitute medical advice. Antidepressant tapering and withdrawal symptom management should be discussed with a qualified healthcare provider. Do not stop or change psychiatric medications without professional guidance.